Scientists report that cancer can be diagnosed and treated with MRI

October 1, 2018, National Research Nuclear University
An MRI machine. Credit: Royal Air Force photo by Sgt. Mitch Moore/Released

Researchers from the National Research Nuclear University MEPhI (Russia) have recently developed a new type of contrast agent for magnetic resonance imaging (MRI) based on biodegradable silicon nanoparticles. The method can be used for both diagnosing and treating cancer.

An MRI is a powerful biomedical diagnostics tool based on the nuclear magnetic resonance of hydrogen atoms (protons). MRI scanners use radio waves to generate images of hydrogen atoms in the magnetic field. The results of this research were published in the Journal of Applied Physics.

Certain imaging methods require the use of to improve the accuracy and information of the image. Contrast imaging in an MRI mostly depends on differences in the longitudinal or transverse relaxation rates. Relaxation is the time protons need to recover to their equilibrium state. This depends on the molecules and atoms around the protons; the rate for healthy and damaged tissues varies.

In some cases, doctors can identify the presence of pathologies with agents that locally affect the relaxation rates within damaged tissues. Combining MRI and contrast agents in research helps scientists acquire better images of inflammations, such as tumorous angiogenesis in cancer.

MEPhI researchers recently developed a new type of a contrast agent based on silicon , which can be used for both diagnosing and treating cancer. Viktor Timoshenko, a professor at MEPhI and Lomonosov Moscow State University, says this is an example of nanotheranostics – a combination of diagnostic and therapeutic methods applied at the nanoscale level. Theranostic MRI contrast agents combine the effects of contrast agents and therapy conducted with medications in nanocapsules and/or additional exposure to physical fields or radiation.

"Since MRI is widely used in cancer diagnostics, developing a new type of a contrast agent that can also be used in cancer eradication therapy is very important for modern healthcare," Timoshenko said.

Nanotheranostic materials must be biocompatible. These materials must also be invisible to the immune system so that it does not destroy them right away. The nanoparticles must not accumulate in the body and their surfaces cannot become contaminated.

Researchers from the MEPhI Institute of Engineering Physics for Biomedicine's Nanotheranostics Laboratory believe that using silicone nanoparticles to detect affected cells is one of the most promising methods in cancer nanotheranostics. The nanoparticles themselves are not toxic to the human body, but subjected to the application of radio waves, can heat up to 42 degrees С and higher (hyperthermia), thus destroying cells locally.

Explore further: Scientists develop novel chemical 'dye' to improve liver cancer imaging

More information: Yu. V. Kargina et al. Investigation of proton spin relaxation in water with dispersed silicon nanoparticles for potential magnetic resonance imaging applications, Journal of Applied Physics (2018). DOI: 10.1063/1.5006846

Related Stories

Scientists develop novel chemical 'dye' to improve liver cancer imaging

May 2, 2017
Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based contrast agent—a chemical "dye" used to enhance the visibility of internal body structures in magnetic resonance imaging ...

Scientists develop an effective marker for cancer diagnosis and therapy

August 27, 2018
A research group consisting of scientists from NUST MISIS, the Technical University of Munich, Helmholtz Zentrum München, the University of Duisburg-Essen, and the University of Oldenburg has developed a system that allows ...

Recommended for you

Sugar supplement slows tumor growth and can improve cancer treatment

November 21, 2018
Mannose sugar, a nutritional supplement, can both slow tumour growth and enhance the effects of chemotherapy in mice with multiple types of cancer.

New mechanism controlling the master cancer regulator uncovered

November 21, 2018
Who regulates the key regulator? The Research Center for Molecular Medicine of the Austrian Academy of Sciences reports online in the journal Science about a newly discovered mechanism by which RAS proteins, central to cancer ...

AI matched, outperformed radiologists in screening X-rays for certain diseases

November 21, 2018
In a matter of seconds, a new algorithm read chest X-rays for 14 pathologies, performing as well as radiologists in most cases, a Stanford-led study says.

Researchers stop spread of cancer in mice by blocking specific molecules

November 21, 2018
Melanoma skin cancer tumors grow larger and are more likely to metastasize due to interactions between a pair of molecules, according to experiments in mice and human cells. The results may restore the potential for a type ...

'Druggable' cancer target found in pathway regulating organ size

November 20, 2018
It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer. It's further known that a major player in this pathway, ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.